CHECKPOINT REGULATOR ANTAGONISTS
Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-LI arc disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific. bispecific and trispecific checkpoint regulator antagonists thereof.
1 - 20 . (canceled)
21 . A trispecific checkpoint regulator antagonist, comprising:
(1) a TIGIT-targeting domain comprising (a) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs):
HCDR1, HCDR2 and HCDR3, wherein the HCDR1 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 6, 11, 15, 17, 20 and 23, wherein the HCDR2 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 7, 9, 12, 13, 16, 18, 21 and 24, and wherein the HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 5, 8, 10, 14, 19, 22 and 25 and (b) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs): LCDR1, LCDR2 and LCDR3, wherein the LCDR1 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 26, 29, 31, 33, 35, 39, 42 and 45, wherein the LCDR2 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 27, 30, 36, 37, 40, 43 and 46, and wherein the LCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOS: 28, 32, 34, 38, 41, 44 and 47, wherein the TIGIT-targeting domain binds specifically to human TIGIT;
(2) a second targeting domain comprising one or more anti-cancer domains; and
(3) a third targeting domain comprising one or more peptide sequences.
22 . The trispecific checkpoint regulator antagonist of claim 21 , wherein the one or more anti-cancer domains comprises one or more anti-checkpoint regulator domains.
23 . The trispecific checkpoint regulator antagonist of claim 22 , wherein the one or more anti-checkpoint regulator domains comprises one or more anti-PD1 domains.
24 . The trispecific checkpoint regulator antagonist of claim 23 , wherein the one or more anti-PD1 domains comprise an anti-PD1 antibody, or an antigen-binding portion thereof, comprising:
(a) a heavy chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 127, 129, 131, 133, 135 and 137; and
(b) a light chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 128, 130, 132, 134, 136 and 138.
25 . The trispecific checkpoint regulator antagonist of claim 22 , wherein the one or more anti-checkpoint regulator domains comprises one or more anti-PD-L1 domains.
26 . The trispecific checkpoint regulator antagonist of claim 22 , wherein the one or more anti-PD-L1 domains comprises an anti-PD-L1 antibody, or an antigen-binding portion thereof, comprising:
(a) a heavy chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 139, 141, 143, 145, 147, 149, 151 and 153; and
(b) a light chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 140, 142, 144, 146, 148, 150, 152 and 154.
27 . The trispecific checkpoint regulator antagonist of claim 21 , wherein the third binding domain comprises AMG386.
28 . The trispecific checkpoint regulator antagonist of claim 21 , wherein the third binding domain comprises a VEGF binding antagonist.
29 . The trispecific checkpoint regulator antagonist of claim 21 , wherein the third binding domain comprises a Tie2 tyrosine kinase receptor antagonist.
30 . The trispecific checkpoint regulator antagonist of claim 21 , wherein the third binding domain comprises a Tie2 tyrosine kinase receptor ligand antagonist.
31 . A method for treating cancer, infectious disease, or autoimmune disease in a subject in need thereof, comprising administering an effective amount of a trispecific checkpoint regulator antagonist, comprising:
(1) a first targeting domain comprising an anti-TIGIT antibody, or an antigen-binding portion thereof, comprising:
(a) a heavy chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 107, 109, 111, 113, 115, 117, 119, 121, 123 and 125; and
(b) a light chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 108, 110, 112, 114, 116, 118, 120, 122, 124 and 126;
(2) a second targeting domain comprising one or more anti-cancer domains; and
(3) a third targeting domain comprising one or more peptide sequences.
32 . The method of claim 31 , wherein the one or more anti-cancer domains comprises one or more anti-checkpoint regulator domains.
33 . The method of claim 32 , wherein the one or more anti-checkpoint regulator domains comprises one or more anti-PD1 domains.
34 . The method of claim 33 , wherein the one or more anti-PD1 domains comprise an anti-PD1 antibody, or an antigen-binding portion thereof, comprising:
(a) a heavy chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 127, 129, 131, 133, 135 and 137; and
(b) a light chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 128, 130, 132, 134, 136 and 138.
35 . The method of claim 32 , wherein the one or more anti-checkpoint regulator domains comprises one or more anti-PD-L1 domains.
36 . The method of claim 32 , wherein the one or more anti-PD-L1 domains comprises an anti-PD-L1 antibody, or an antigen-binding portion thereof, comprising:
(a) a heavy chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 139, 141, 143, 145, 147, 149, 151 and 153; and
(b) a light chain variable region having an amino acid sequence that is about 80% to about 100% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 140, 142, 144, 146, 148, 150, 152 and 154.
37 . The method of claim 31 , wherein the third binding domain comprises AMG386.
38 . The method of claim 31 , wherein the third binding domain comprises a VEGF binding antagonist.
39 . The method of claim 31 , wherein the third binding domain comprises a Tie2 tyrosine kinase receptor antagonist.
40 . The method of claim 31 , wherein the third binding domain comprises a Tie2 tyrosine kinase receptor ligand antagonist.